The Role of Topotecan in the Treatment of Brain Metastases

Oncologist

Volumn 9, Issue 1, 2004, Pages 68-79

  Wong, Eric T ^a,b   Berkenblit, Anna ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Drug therapy; Neoplasms; Temozolomide; Topoisomerase I inhibitor; Topotecan

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; LACTONE DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLNITRONITROSOGUANIDINE; NAVELBINE; RADIOSENSITIZING AGENT; STEROID; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

AGITATION; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER CHEMOTHERAPY; CASE STUDY; CLINICAL TRIAL; CONFUSION; DRUG CLEARANCE; DRUG PENETRATION; DRUG POTENTIATION; FEBRILE NEUTROPENIA; HALLUCINATION; HEADACHE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MENINGEAL METASTASIS; MOTOR DYSFUNCTION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VISUAL DISORDER;

AGED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; TOPOTECAN;

EID: 1642579676     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-1-68     Document Type: Review

References (61)

1. Wen PY, Black PM, Loeffler JS. Treatment of metastatic cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2655-2670.
2. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Huntingt) 1999;13:941-954, 957-961; discussion 961-962, 969.
3. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996;7:337-344.
4. Davey P. Brain metastases. Curr Probl Cancer 1999;23:59-98.
5. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:983-1018.
6. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002. Available at: http://seer.cancer.gov/CSR/1973_1999/, accessed 02/17/03.
7. Bunn PA Jr, Nugent JL, Matthews MJ. Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol 1978;5:314-322.
8. Lagerwaard FJ, Levendag PC, Nowak PJ et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
9. Markesbery WR, Brooks WH, Gupta GD et al. Treatment for patients with cerebral metastases. Arch Neurol 1978;35:754-756.
10. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
11. Bindal RK, Sawaya R, Leavens ME et al. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79:210-216.
12. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789-796.
13. Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390-1396.
14. Alexander E 3rd, Moriarty TM, Davis RB et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:34-40.
15. Shaw E, Scott C, Souhami L et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of Radiation Therapy Oncology Group protocol (90-05). Int J Radiat Oncol Biol Phys 1996;34:647-654.
16. Lee JS, Murphy WK, Glisson BS et al. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989;7:916-922.
17. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327-334.
18. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832-839.
19. Boogerd W, Dalesio O, Bais EM et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-980.
20. Carey RW, Davis JM, Zervas NT. Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rep 1981;65:793-795.
21. Abrey LE, Olson JD, Raizer JJ et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-265.
22. von Pawel J, Gatzemeier U, Pujol JL et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
23. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
24. Depierre A, von Pawel J, Hans K et al. Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997;18(suppl 1):35.
25. Eckardt J, Gralla R, Palmer MC et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996;7(suppl 5):107.
26. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-3352.
27. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257-262.
28. Sung C, Blaney SM, Cole DE et al. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994;54:5118-5122.
29. Blaney SM, Cole DE, Balis FM et al. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993;53:725-727.
30. Baker SD, Heideman RL, Crom WR et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37:195-202.
31. Zamboni WC, Luftner DI, Egorin MJ et al. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 2001;12:119-122.
32. Zamboni WC, Gajjar AJ, Heideman RL et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783-789.
33. Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997;15:3121-3128.
34. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-1525.
35. Oberhoff C, Kieback DG, Würstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24:256-260.
36. Manegold C, Pawel JV, Scheithauer W et al. Response of SCLC brain metastases on topotecan (SK&F 104864) therapy. Ann Oncol 1996;7(suppl 5):106-107.
37. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
38. Schütte W, Manegold C, von Pawel JV. Topotecan in the therapy of brain metastases in lung cancer. Onkologie 1998;21(suppl 4):25-27.
39. Schütte W, Manegold C, von Pawel JV et al. Topotecan-a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 1999;33:354-363.
40. Korfel A, Oehm C, von Pawel J et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study. Eur J Cancer 2002;38:1724-1729.
41. Stupp R, Ostermann S, Leyvraz S et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 2001;20:59a.
42. Agarwala SS, Reyderman L, Statkevich P et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol 1998;9(suppl 4):138.
43. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-2771.
44. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-266.
45. Brandes AA, Ermani M, Basso U et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 2001;12:255-257.
46. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593.
47. 6-methylguanine. Cancer Res 2001;61:53-58.
48. Castellino RC, Elion GB, Keir ST et al. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 2000;45:345-349.
49. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
50. Prados M. Temozolomide in combination with other cytotoxic agents. Semin Oncol 2001;28(suppl 13):24-33.
51. Eckardt JR, Martin KA, Schmidt AM et al. A phase I trial of IV topotecan in combination with oral temozolomide daily times 5 every 28 days. Proc Am Soc Clin Oncol 2002;21:83b.
52. Kim JH, Kim SH, Kolozsvary A et al. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992;22:515-518.
53. Mattern MR, Hofmann GA, McCabe FL et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991;51:5813-5816.
54. Reboul F, Vincent P, Brewer Y et al. Chemoradiotherapy for brain metastases of lung origin. Results of a phase II study. Proc Am Soc Clin Oncol 1996;15:373.
55. Robinet G, Thomas P, Breton JL et al. Phase III study of early versus delayed whole brain radiotherapy (WBRT) with concurrent cisplatin and vinorelbine combination in brain metastasis (BM) of non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:453a.
56. Fisher BJ, Scott C, Macdonald DR et al. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 2001;19:1111-1117.
57. Fisher B, Won M, Macdonald D et al. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 2002;53:980-986.
58. Grüschow K, Klautke G, Fietkau R. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur J Cancer 2002:38:367-374.
59. Russell AH, Pajak TE, Selim HM et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991;21:637-643.
60. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
61. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992;10:1498-1502.